IMCF-106C is a fusion protein commercialized by Immunocore, with a leading Phase II program in Endometrial Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IMCF-106C’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for IMCF-106C is expected to reach an annual total of $108 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
IMCF-106C is under development for the treatment of non-small cell lung cancer, synovial sarcoma, small cell lung cancer, ovarian cancer, endometrial cancer, urothelial carcinoma, triple-negative breast cancer , cutaneous melanoma, mucosal melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia and uveal melanoma. It comprises of T cell receptor (TCR) with an anti-CD3 single-chain antibody fragment (scFv). The drug candidate is developed based on Immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) technology. It is administered through intravenous route. The drug candidate acts by targeting preferentially expressed antigen in melanoma (PRAME).
Immunocore is a biotechnology company. It focuses on the development of immunotherapeutic drugs for the treatment of cancer, infectious diseases, and autoimmune diseases. The company develops its drugs using proprietary T cell receptor (TCR) technology. Its products under development include IMC-C103C, IMC-F106C, IMC-I109V, IMC-M113V and IMCgp100. The company works in collaboration with various pharmaceutical companies, to develop its product candidates for the treatment of metastatic cutaneous melanoma; cancer; and other indications. It has presence in the UK, the US, Australia, New Zealand and Asia, Europe. Immunocore is headquartered in Oxfordshire, the UK.
The company reported revenues of (British Pounds) GBP143.7 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of GBP26.5 million in FY2021. The operating loss of the company was GBP39.6 million in FY2022, compared to an operating loss of GBP135.2 million in FY2021. The net loss of the company was GBP41.2 million in FY2022, compared to a net loss of GBP131.5 million in FY2021. The company reported revenues of GBP44.5 million for the first quarter ended March 2023, a decrease of 7.3% over the previous quarter.
For a complete picture of IMCF-106C’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.